Results 31 to 40 of about 21,302 (228)

Direct oral anticoagulant blood level monitoring in daily practice

Thrombosis Update, 2021
Introduction: Routine monitoring is not required in direct oral anticoagulant (DOAC) treatment, yet it is frequently performed. Guidance on the interpretation and management of DOAC level measurements is lacking and it is key to investigate which ...
R. Bavalia, J.E. Veenhuizen, R.C.C. Hengeveld, D. Braeken, A.J.W. Gulpen, H. Ten Cate, S. Middeldorp, Y.M.C. Henskens, B.A. Hutten, M. Coppens, A.K. Stroobants   +10 more
doaj   +1 more source

A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter

Frontiers in Medicine, 2021
Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA) assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated a new device, called DOAC Filter, and its usefulness in this setting.
C. Farkh, Syrine Ellouze, Louis Gounelle, Mama Sad Houari, J. Duchemin, V. Proulle, M. Fontenay, X. Delavenne, Georges Jourdi   +8 more
semanticscholar   +1 more source

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients

Diagnostics, 2021
Background: The effect of direct oral anticoagulants (DOAC) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa, is a well-known problem and can cause both false positive and negative results.
Jana Úlehlová, Barbora Piskláková, Eliška Ivanovová, Jana Procházková, Pavla Bradáčová, Aleš Kvasnička, David Friedecký, Luděk Slavík   +7 more
doaj   +1 more source

Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018.

Revista Española de Cardiología, 2021
INTRODUCTION AND OBJECTIVES The incidence and prevalence of atrial fibrillation (AF), a major risk factor for stroke, has increased substantially in the past few years.
J. Díaz-Guzmán, R. Freixa-Pamias, J. García-Alegría, A. P. Pérez Cabeza, I. Roldán-Rabadán, B. Antolin‐Fontes, P. Rebollo, A. Llorac, Mar Genís-Gironés, Carlos Escobar-Cervantes   +9 more
semanticscholar   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +1 more source

Venous thromboembolic complications in lymphoma patients [PDF]

Medicinski Podmladak, 2020
Lymphomas represent a heterogeneous group of malignant hematological diseases with high risk for development of venous thromboembolic complications (VTE). Consequently, VTE significantly impacts morbidity and mortality in these patients.
Otašević Vladimir, Antić Darko, Mihaljević Biljana   +2 more
doaj   +1 more source

Broad activity against fungal phytopathogens of marine Astrosphaeriella cf. striatispora BUCS 055-1 [PDF]

Songklanakarin Journal of Science and Technology (SJST), 2021
Inhibitory activity against all five fungal phytopathogens; Colletotrichum capsici DOAC 1511, C. gloeosporioides DOAC 0782, Fusarium oxysporum DOAC 1808, F. subglutinans DOAC 0761 and Pestalotiopsis sp.
Sudarat Suanjit, Watanalai Panbangred, Apiradee Pilantanapak   +2 more
doaj   +1 more source

The pathogenesis of microthrombi in COVID‐19 cannot be controlled by DOAC: NETosis should be the target

Journal of Internal Medicine, 2021
We read with interest the data of DOAC-treated patients infected by SARS-CoV-2 compared to the no-DOAC-treated patients. The study by Flam et al [1] is of utmost importance since it sheds light on one of the most controversial aspects of COVID-19 disease:
E. Gremese, G. Ferraccioli
semanticscholar   +1 more source

The new way of Dabigatran reversal – Idarucizumab

Journal of Education, Health and Sport, 2019
Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański, Krystian Ciechański, Magda Ciechańska, Jarosław Szponar   +3 more
doaj   +1 more source

Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants – A Retrospective Cohort Study in Health Insurance Claims Data

Patient Preference and Adherence, 2021
Lucas Wirbka, Walter Emil Haefeli, Andreas Daniel Meid On behalf of ARMIN Study GroupDepartment of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, 69120, GermanyCorrespondence: Andreas Daniel MeidDepartment of ...
Wirbka L, Haefeli WE, Meid AD
doaj